You searched for:"Maria Celeste Osório Wender"
We found (11) results for your search.-
Validation of the Brazilian 10-item Cervantes Scale for the assessment of menopausal symptoms
Rev Bras Ginecol Obstet. 2024;46:e-rbgo7
Summary
Validation of the Brazilian 10-item Cervantes Scale for the assessment of menopausal symptoms
Rev Bras Ginecol Obstet. 2024;46:e-rbgo7
Views207See moreAbstract
Objective:
To validate the 10-item Cervantes Scale (CS-10) among Brazilian women.
Methods:
This is a cross-sectional observational study involving women in the community aged 40–55 years in the Southern region of Brazil. They completed a general health, habits and socio-demographic questionnaire, the CS-10 and the Women’s Health Questionnaire (WHQ). Women unable to understand the survey, not consenting to participate, or having incapacity imposing difficulties during the completion of the questionnaire were excluded. A Confirmatory Factor Analysis (CFA) was conducted with the AMOS 16.0 software. Chi-square of degrees of freedom (χ2/df), the Comparative Fit Index (CFI), the Tucker-Lewis Index (TLI) and the Root-Mean-Square Error of Approximation (RMSEA) were used as indices of goodness of fit. Cronbach’s alpha coefficient was used for internal consistency.
Results:
A total of 422 women were included (premenopausal n=35, perimenopausal n=172, postmenopausal n=215). The CFA for the CS-10 showed a good fit (χ²/df=1.454, CFI=0.989; TLI=0.985; RMSEA=0.033; CI 90%=0.002-0.052; PCLOSE=0.921; Model p=0.049). Good reliability was established in CS-10 and WHQ (Cronbach’s alpha=0.724). Postmenopausal women had higher total CS-10 scores (p≤0.0001), reflecting worse quality of life (QoL) related to menopause symptoms and confirming the greater symptomatology evaluated by high total scores for WHQ found in this population when compared to those in the premenopausal period (p=0.041).
Conclusion:
The CS-10 is a consistent tool for health-related QoL in Brazilian mid-aged women.
-
Febrasgo Position Statement
Misoprostol use in obstetrics: Number 6 – June 2023
Rev Bras Ginecol Obstet. 2023;45(6):356-367
Summary
Febrasgo Position StatementMisoprostol use in obstetrics: Number 6 – June 2023
Rev Bras Ginecol Obstet. 2023;45(6):356-367
-
Editorial
Increase in cesarean sections in Brazil – a call to reflection
Rev Bras Ginecol Obstet. 2023;45(3):109-112
Summary
EditorialIncrease in cesarean sections in Brazil – a call to reflection
Rev Bras Ginecol Obstet. 2023;45(3):109-112
Views2Cesarean rates have increased progressively over the decades in all countries, and a high figure of 56% was reached in Brazil, second only to the Dominican Republic (59%) and well above the average of developing countries. This scenario in our country motivated government and private sector initiatives, among which the Projeto Parto Adequado (“Adequate Childbirth […]See more -
Original Article
Factors Associated with the Chance of Carrying out a Primary Cesarean in a University Hospital
Rev Bras Ginecol Obstet. 2022;44(7):640-645
Summary
Original ArticleFactors Associated with the Chance of Carrying out a Primary Cesarean in a University Hospital
Rev Bras Ginecol Obstet. 2022;44(7):640-645
Views4See moreAbstract
Objective
The present study seeks to identify the associated factors that increased primary cesarean delivery rates.
Methods
This was a cross-sectional study that evaluated the number of primary cesarean sections performed in the years 2006 and 2018 at the Hospital de Clínicas de Porto Alegre (HCPA, in the Portuguese acronym), through the collection of data from the medical records of the patients.
Results
Advanced maternal age, twin pregnancy, and higher body mass index (BMI) became more frequent in 2018 in comparison with 2006. To mitigate the impact of confounding in comparisons among groups, we made an adjustment by propensity scores and detected significant differences when comparing both age groups on twin pregnancy rates, gestational diabetes mellitus, and thyroid disease.
Conclusion
Data from the present study can be used to prevent and improve the management of morbidities, impacting on better outcomes in obstetrical practice.
-
Febrasgo Position Statement
Initial evaluation in the climacteric – Number 5 – May 2022
Rev Bras Ginecol Obstet. 2022;44(5):548-556
Summary
Febrasgo Position StatementInitial evaluation in the climacteric – Number 5 – May 2022
Rev Bras Ginecol Obstet. 2022;44(5):548-556
-
Febrasgo Position Statement
Genitourinary Syndrome of Menopause – Number 3 – March 2022
Rev Bras Ginecol Obstet. 2022;44(3):319-324
Summary
Febrasgo Position StatementGenitourinary Syndrome of Menopause – Number 3 – March 2022
Rev Bras Ginecol Obstet. 2022;44(3):319-324
-
Original Article
Validation of the Six-item Female Sexual Function Index in Middle-Aged Brazilian Women
Rev Bras Ginecol Obstet. 2019;41(7):432-439
Summary
Original ArticleValidation of the Six-item Female Sexual Function Index in Middle-Aged Brazilian Women
Rev Bras Ginecol Obstet. 2019;41(7):432-439
Views5See moreAbstract
Objective
To validate the six-item female sexual function index (FSFI-6) in middleaged Brazilian women.
Methods
Cross-sectional observational study, involving 737 (premenopausal n = 117, perimenopausal n = 249, postmenopausal n = 371) Brazilian sexually active women, aged between 40 and 55 years, not using hormonal contraceptive methods. The Brazilian FSFI-6 was developed from the translation and cultural adaptation of the Portuguese FSFI-6 version. The participants completed a general questionnaire, the FSFI-6, and the menopause rating scale (MRS). The validation was performed by AMOS 16.0 software (SPSS, Inc., Chicago, IL, USA) for a confirmatory factor analysis (CFA). The chi-square of degrees of freedom (χ2/df), the comparative fit index (CFI), the Tucker- Lewis index (TLI) and the root-mean-square error of approximation (RMSEA) were used as indices of goodness of fit. Cronbach α coefficient was used for internal consistency.
Results
The process of cultural adaptation has not altered the Brazilian FSFI-6, as compared with the original content. The CFA for the FSFI-6 score showed an acceptable fit (χ2/df = 3.434, CFI = 0.990, TLI = 0.980, RMSEA = 0.058, 90% confidence interval (90%CI) = 0.033-0.083, p ≤ 0.001) and a good reliability was established in FSFI-6 and MRS (Cronbach α = 0.840 and = 0.854, respectively). In addition, 53.5% of the sample had low sexual function.
Conclusion
The FSFI-6 was translated and adapted to the Brazilian culture and is a consistent and reliable tool for female sexual dysfunction screening in Brazilianmiddleaged women.
-
Original Article
Premenstrual Syndrome Diagnosis: A Comparative Study between the Daily Record of Severity of Problems (DRSP) and the Premenstrual Symptoms Screening Tool (PSST)
Rev Bras Ginecol Obstet. 2018;40(1):20-25
Summary
Original ArticlePremenstrual Syndrome Diagnosis: A Comparative Study between the Daily Record of Severity of Problems (DRSP) and the Premenstrual Symptoms Screening Tool (PSST)
Rev Bras Ginecol Obstet. 2018;40(1):20-25
Views0Abstract
Objective
To validate the premenstrual symptoms screening tool (PSST) in relation to the daily record of severity of problems (DRSP) for premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) diagnoses.
Methods
A cross-sectional study with 127 women (20 45 years) with PMS complaints. The women were evaluated in terms of weight, height and body mass index (BMI). After using the primary care evaluation of mental disorders (PRIME-MD) questionnaire to exclude the diagnosis of depression, the PSST was completed and the women were instructed to fill out the DRSP for two consecutive menstrual cycles. The agreement between the two questionnaires was assessed by the Kappa (k) and the prevalence-adjusted, bias-adjusted kappa (PABAK) values.
Results
Two-hundred and eighty-two women met the eligibility criteria and answered the PSST. The DRSP was completed for two cycles by 127 women. The percentages of women with PMS and PMDD diagnoses by the DRSP were 74.8% and 3.9% respectively; by PSST, the percentages were41.7% and 34.6% respectively. The number of patients considered “normal” (with symptoms below the threshold for the diagnosis of PMS) was similar in both questionnaires. There was no agreement (Kappa = 0.12) in the results of PMS/ PMDD diagnosis (the PABAK coefficient confirmed this result = 0.39). The PSST had a high sensitivity (79%) and a low specificity (33.3%) for PMS/PMDD diagnosis.
Conclusion
The PSST should be considered a diagnostic screening tool. Positive PMS/PMDD cases by PSST should be further evaluated by DRSP to confirm the diagnosis.
Key-words diagnosispremenstrual dysphoric disorderpremenstrual syndromequestionnaireSigns and symptomsSee more
Search
Search in:
Tag Cloud
breast (42) breast cancer (42) breast neoplasms (95) Cesarean section (72) endometriosis (66) infertility (56) Maternal mortality (43) menopause (82) obesity (58) postpartum period (40) pregnancy (225) Pregnancy complications (99) Prenatal care (68) prenatal diagnosis (50) Prevalence (41) Quality of life (51) risk factors (94) ultrasonography (79) urinary incontinence (40) women's health (48)